Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

VERITAC-2: Phase 3 monotherapy clinical trial in patients with metastatic breast cancer (ClinicalTrials.gov Identifier: NCT05654623) TACTIVE-U: Phase 1b/2 combination umbrella trial evaluating ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) ? a rare genetic bleeding condition that causes enlargements and ...

As the decade progressed, other novel targeted agents, including lapatinib and bevacizumab were developed to disrupt additional growth signalling pathways in certain breast cancer subtypes.

We are conducting clinical trials to evaluate the use of ribociclib in combination with fulvestrant and ... of LABC in New York women with the goal of translating the Akt/mTOR pathway to treatment.

In fact, Wilkinson hopes an agreement between the Pathways Alliance consortium, Ottawa and Alberta can soon be reached to get one of the world’s largest carbon capture networks moving ...

However, this doesn’t have to be the case for your business. By building strong career pathways and offering meaningful training programs, you can retain top talent and help them thrive within ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

“Therefore, I think it is important for us to then think … how do we create a lot more choices, a lot more flexible pathways to cater to the needs of the different students and also to meet ...